MONJUVI (TAFASITAMAB-CXIX) IN COMBINATION WITH LENALIDOMIDE: A 2L Outpatient Targeted Immunotherapy for Adult Patients with R/R DLBCL Who Are Not Eligible for Transplant.
This program is not CME accredited.
This event begins in
-
Days
-
Hours
-
Minutes
A zoom link will be available the day of the event.
- March 27, 2025
- 8:00 PM EST
